Rossella Renso

ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine

Diletta Fontana, Mario Mauri, Rossella Renso et al. · Nature Communications · 2020 · 48 citations · Full text

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Margherita Maffioli, Toni Giorgino, Barbara Mora et al. · Blood Advances · 2019 · 25 citations · Full text

Consecutive Patients, Lymphoid Neoplasia, Hematological Malignancy +12

Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications

Angelo Belotti, Lorena Duca, Lorenza Borin et al. · Leukemia Research · 2014 · 23 citations

Hematological Malignancy, Conventional Intensive Chemotherapy, Iron Metabolism +11

Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The <scp>ARES</scp> trial

Bianca Rocca, Alberto Tosetto, Giovanna Petrucci et al. · American Journal of Hematology · 2024 · 17 citations · Full text

Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study

Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti et al. · British Journal of Haematology · 2022 · 13 citations